91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
91黑料's partnership with Advarra will integrate 91黑料’s global clinical trial solutions and services with Advarra’s site?CTMSs,?eISF, and?eSource?systems, which are already used by more than 50,000 investigators worldwide, including researchers at 90 of the top 125 academic medical centres.
-
91黑料 and Advarra partnership creates an integrated site-centric system that tackles operational bottlenecks and simplifies study execution, addressing sponsors most pressing challenges.
-
91黑料 and Advarra have partnered to create a connected network of clinical trial sites that integrates 91黑料’s global trial solutions with Advarra’s site technologies, aiming to streamline study operations, boost efficiency, and expand trial access.
-
91黑料 and Advarra have formed a partnership to create a connected, research ready site network that integrates 91黑料’s clinical trial services with Advarra’s site-facing technology to streamline study startup and trial execution. The collaboration aims to reduce administrative burden, enhance operational visibility, and broaden trial access by standardising workflows for both established and emerging research sites.
-
91黑料 plc and Advarra, a provider of connected, intelligence-powered research technology, have entered a partnership agreement to introduce a new ‘research-ready,’ connected site network model for clinical trials.
-
Digital health technologies are rapidly becoming essential to clinical trial strategies as regulators and sponsors embrace them to streamline operations, reduce patient burden, and generate higher?quality real?world data.
-
Study startup, and specifically, feasibility, site selection and activation, remains one of the most critical yet challenging early phases of clinical trial delivery. The solution to persistent startup bottlenecks? Refocusing on site centricity.
-
How contract standardisation, proactive budget alignment, and AI-enabled negotiation tools can reduce site activation delays and turn agreements into strategic accelerators.
-
Why persistent communication breakdowns between sponsors, CROs, and sites undermine startup efficiency—and how bidirectional, site-informed engagement models can improve collaboration and momentum.
-
How practical AI applications can streamline contracts and startup workflows while preserving the central role of investigators, site staff, and patient relationships.
